NorthCoast Asset Management LLC
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1665198
STAMFORD, CT
Position in ALNY
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$647,843
-$129,562 QoQ
Shares Held
1,958
+0.2% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026NorthCoast Asset Management LLC holds $49,985,622 across 8 Biotechnology names. ALNY ranks #6 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
90,885 | $40,583,787 | |
| 2 | INCY |
Incyte Corp
|
31,820 | $2,994,898 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
35,585 | $2,010,196 | |
| 4 | ARGX |
Argenx SE
|
2,034 | $1,485,328 | |
| 5 | DRTS |
Alpha Tau Medical Ltd.
|
147,138 | $1,040,265 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
1,958 | $647,843 | |
| 7 | EXEL |
Exelixis, Inc.
|
14,885 | $638,417 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
757 | $584,888 |
All Filings in ALNY
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $647,843 | 1,958 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $777,405 | 1,955 | Shares | Sole | 2026-02-20 | |
| 2025-09-30 | $1,188,792 | 2,607 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $766,311 | 2,350 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $634,276 | 2,349 | Shares | Sole | 2025-05-19 | |
| 2024-12-31 | $621,453 | 2,641 | Shares | Sole | 2025-08-25 | |
| 2024-09-30 | $668,597 | 2,431 | Shares | Sole | 2024-11-15 | |
| No filing history on record for this holder in this stock. | ||||||